Shares of Horizon Pharma PLC (NASDAQ:HZNP) traded down 1.07% on Wednesday, reaching $10.19. The stock Fell -46.65 percent over the past six months. Horizon Pharma PLC earned a media sentiment score of 0.03 on AlphaOne's scale. BlackRock Inc. now owns 13,261,212 shares of the biopharmaceutical company's stock valued at $196,001,000 after buying an additional 13,241,875 shares during the period.
Shares of Randgold Resources Limited (NASDAQ:GOLD) are making a strong comeback as they have jumped 41.18% since bottoming out at $67.54 on December 15, 2016. Cls Invests Limited Company has 0% invested in Procter & Gamble Co (NYSE:PG). Stevens Capital Management LP bought a new stake in Horizon Pharma PLC during the first quarter worth about $173,000. Teachers Advisors LLC now owns 864,348 shares of the biopharmaceutical company's stock valued at $15,671,000 after buying an additional 606,842 shares during the last quarter. Finally, First Mercantile Trust Co. raised its stake in Horizon Pharma PLC by 2.7% in the first quarter. Envestnet Asset Management Inc. now owns 120,714 shares of the biopharmaceutical company's stock valued at $1,954,000 after buying an additional 800 shares in the last quarter. About 4.22 million shares traded. The company's market capitalization is $1.66 billion. When you compare the EPS history with the stock price history, it helps you determine the most likely future direction of the stock price. The Company has 52-week high of $23.44 and 52-week low of $9.45.
The forward P/E ratio stands at 8.77. Return on equity measures is a company's ability to turn an investor's equity into profit. The business had revenue of $220.90 million during the quarter, compared to analysts' expectations of $248.71 million. During the same quarter previous year, the firm posted $0.34 earnings per share.
The company reported an impressive total revenue of 981.12 Million in the last fiscal year. Horizon Pharma PLC has a consensus rating of "Buy" and a consensus target price of $21.38. Highbridge Capital Management LLC raised its stake in Horizon Pharma PLC by 128.2% in the first quarter. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of US and global copyright & trademark law. There is a large variety of Financial Ratios that can be considered while making an investment decision but here in the case of Horizon Pharma plc (HZNP), we will discuss a few. Mizuho reaffirmed a "buy" rating and issued a $25.00 price target on shares of Horizon Pharma PLC in a report on Wednesday, February 22nd. Jefferies Group LLC set a $14.00 price target on shares of Horizon Pharma PLC and gave the company a "buy" rating in a report on Tuesday, May 9th.More news: Senate chairman: Flynn has not responded to subpoena
More news: Ford to cut 1400 jobs by the end of this summer
More news: Trump complains of 'greatest witch hunt'
02/27/2017 - Guggenheim began new coverage on Horizon Pharma, Inc. giving the company a "buy" rating. They now have a United States dollars 20 price target on the stock.
In recent trading day Horizon Pharma Public Limited Company (HZNP) stock showed the move of -2.56% with the closing price of $10.66. The stock of Horizon Pharma PLC (NASDAQ:HZNP) has "Buy" rating given on Tuesday, November 8 by Mizuho. Three investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. They may also be used to assist the trader figure out proper support and resistance levels for the stock.
In other news, EVP Robert Carey sold 31,808 shares of the firm's stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $16.03, for a total value of $509,882.24. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
In other news, Director Michael G. Grey bought 10,000 shares of the firm's stock in a transaction on Wednesday, May 10th. The disclosure for this sale can be found here. Prudential Financial Inc. now owns 16,680 shares of the biopharmaceutical company's stock valued at $247,000 after buying an additional 420 shares in the last quarter. Horizon Pharma Public Limited Company's RSI is presently sitting at 31.74.